SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Brookline Capital Markets upped their Q3 2026 earnings estimates for SAB Biotherapeutics in a research report issued to clients and investors on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now expects that the company will post earnings of ($0.24) per share for the quarter, up […]
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | HC Wainwright Issues Pessimistic Outlook for SABS Earnings | 0 | 12.58 | 10-08-2026 |
| 2 | XFOR FY2029 EPS Boosted by Brookline Capital Markets | 0 | 12.66 | 10-08-2026 |
| 3 | Zacks Research Analysts Increase Earnings Estimates for ARWR | 0 | 11.84 | 10-08-2026 |
| 4 | Zacks Research Lifts Earnings Estimates for Bread Financial | 0 | 11.13 | 10-08-2026 |
| 5 | FY2026 EPS Estimates for Jacobs Solutions Raised by KeyCorp | 0 | 11.18 | 10-08-2026 |
| 6 | Satellogic Q1 EPS Estimate Increased by Northland Securities | 0 | 12.58 | 10-08-2026 |
| 7 | FY2029 Earnings Forecast for IN8bio Issued By HC Wainwright | 0 | 14.81 | 10-08-2026 |
| 8 | Brokers Set Expectations for Galaxy Digital Q3 Earnings | 0 | 11.84 | 10-08-2026 |
| 9 | Erste Group Bank Expects Stronger Earnings for UBS Group | 0 | 10.45 | 10-08-2026 |
| 10 | Geo Group Q3 EPS Estimate Boosted by Northland Securities | 0 | 11.83 | 10-08-2026 |